General Information
As of 02/09/2012
|
| NAV |
$12.31 |
| NAV Daily Change |
($0.06) |
| % Yield |
0 |
| % SEC Yield |
N/A |
| % YTD Return (as of 12/31/2011) |
-7.36 |
| Objective* |
Equity - Sector Health |
| Peer* |
HL SG |
* Key
Portfolio Statistics
|
| % Unrealized Gain YTD |
-.89 |
| Net Assets (Mil $) N/A |
296.53 |
| % Turnover N/A |
84.00 |
Fees
|
| % Max Sales Load |
.00 |
| % Min Sales Load |
.00 |
| % Max Deferred Load |
.00 |
Expenses
|
| % Max 12b-1 Fee |
.00 |
| % Max Management Fee |
1.00 |
| % Redemption Fee |
.00 |
| % Expense Ratio |
1.08 |
Allocation
|
| Large Growth |
.00 |
| Large Value |
.00 |
| Small Growth |
53.86 |
| Small Value |
.00 |
| Foreign Stock |
18.23 |
| Emerging Market |
.00 |
| Precious Metals |
.00 |
| Intermediate Bond |
19.71 |
| Foreign Bond |
.00 |
| High Yield Bond |
.00 |
Portfolio Information |
| Composition |
| As of N/A |
% of Net Assets |
| Stock |
96.68 |
| Cash |
3.41 |
| Bonds |
.00 |
| Preferred |
.00 |
| Convertibles |
.00 |
| Foreign Stock |
26.05 |
| Foreign Bonds |
.00 |
| Hedge |
.00 |
| Other |
-.08 |
Sector / Country Weightings
|
| As of 09/30/2011 |
% of Portfolio |
| Health |
42.69 |
| Services |
23.46 |
| Other |
16.73 |
| Industrial Cyclical |
8.17 |
| Technology |
4.94 |
| Retail Trade |
2.63 |
| Finance |
1.38 |
| N/A |
N/A |
| N/A |
N/A |
Portfolio Holdings |
Top Equity Holdings
(As of 09/30/2011) |
% of Portfolio |
Value (Mil$) |
|
| MYRIAD GENETICS INC |
5.09 |
9.95 |
| UCB SA |
4.99 |
9.76 |
| INSULET CORP |
4.94 |
9.67 |
| ADVISORY BOARD CO/THE |
4.79 |
9.38 |
| QUIDEL |
4.60 |
9.00 |
| BIOMERIEUX SA |
4.36 |
8.52 |
| DEXCOM |
4.09 |
8.01 |
| OPTIMER PHARMACEUTICALS |
3.86 |
7.56 |
| ENDOLOGIX |
3.68 |
7.20 |
| N/A |
N/A |
N/A |
|
|
This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Funds over the next 6 months.
| Zacks Rank |
Definition |
| #1 |
Strong Buy |
| #2 |
Buy |
| #3 |
Hold |
| #4 |
Sell |
| #5 |
Strong Sell |
| S&P |
500 |
Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Zacks Premium Research
|
Zacks Mutual Fund Rank
|
| |
Find similar funds that have a Mutual Fund Rank.
Find Similar Funds Now  |
Zacks Commentary for EXLSX
|
|
|
|
Stock Holding Statistics
% of Net Assets
|
| As Of |
N/A |
| Total Issues |
32 |
| Avg. P/E |
28.47 |
| Avg. P/Book |
5.89 |
| Avg. EPS Growth |
16.25 |
| Avg. Market Value (Mil $) |
2,593 |
Risk
|
|
3 Year |
5 Year |
10 Year |
| Beta |
0.76 |
0.96 |
0.97 |
| Alpha |
6.41 |
2.82 |
1.33 |
| R Squared |
0.67 |
0.69 |
0.71 |
| Std. Dev. |
17.61 |
21.94 |
18.55 |
| Sharpe |
1.07 |
0.05 |
3.00 |
Shareholder Information
|
| Manager |
Team Managed |
| Since |
N/A |
| Manager Rating * SEE EXPLANTION |
N/A |
| Inception Date |
06/21/2001 |
| Shareholders |
0 |
| Dividends Paid |
A |
| Minimum Initial Investment |
$2,000 |
| Minimum Subsequent Investment |
$0 |
| IRA Minimum |
$0 |
| IRA Available |
Y |
Check Writing |
N |
Phone Invest |
Y |
| Phone Exchange |
Y |
Phone Redeem |
Y |
Auto Invest |
Y |
| Wire Redeem |
Y |
Wire Fee |
Y |
Wire Transfer |
Y |
Contact Information
|
| Family |
Manning&Napier |
| Address |
PO Box 182454
Columbus, OH 43218-2454 |
| Phone |
800 466-3863 |
|
Sponsored Links 
